专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2002026236A1 TUMOR CELL KILLING BY CELL CYCLE CHECKPOINT ABROGATION COMBINED WITH INHIBITION OF THE "CLASSICAL" MITOGEN ACTIVATED PROTEIN (MAP) KINASE PATHWAY 审中-公开
标题翻译：肿瘤细胞死亡细胞周期检查点组合抑制“经典”激素启动蛋白（MAP）激酶途径
公开(公告)号：WO2002026236A1
公开(公告)日：2002-04-04
申请号：PCT/US2001/030508
申请日：2001-09-28
申请人： VIRGINIA COMMONWEALTH UNIVERSITY , DENT, Paul , GRANT, Steven , MCKINSTRY, Robert , DAI, Yum
发明人： DENT, Paul , GRANT, Steven , MCKINSTRY, Robert , DAI, Yum
IPC分类号： A61K31/55
CPC分类号： A61K41/00 , A61K31/52 , A61K31/522 , A61K31/535 , A61K31/55 , A61K31/365 , A61K31/35 , A61K31/275 , A61K31/165 , A61K2300/00
摘要： The present invention provides a method for treating cancer by promoting apoptosis and reducing clonogenic survival of cancer cells. The method encompasses co-administering 1) a cell cycle checkpoint abrogation agent (for example, UCN-01 or caffeine) and 2) an inhibitor of a compensatory cytoprotective pathway, such as an agent that inhibits the MEK 1/2 pathway (e.g. PD98059, U0126, or PD184352) or an agent that inhibits the PI 3 pathway (e.g. LY294002 or wortmanin). In addition, because the co-administration step also radiosensitizes cancer cells, the method additionally encompasses the administration of radiation to further reduce clonogenic survival of cancer cells. The method promotes apoptosis and reduces clonogenic survival in many types of cancer cells, including leukemia cells, prostate cancer cells, breast cancer cells, myeloma cells, and lymphoma cells.
摘要翻译：本发明提供了通过促进细胞凋亡和降低癌细胞的克隆生存来治疗癌症的方法。该方法包括共同施用1）细胞周期检查点废除剂（例如UCN-01或咖啡因）和2）补偿性细胞保护途径的抑制剂，例如抑制MEK 1/2途径的试剂（例如PD98059 ，U0126或PD184352）或抑制PI3途径的试剂（例如LY294002或wortmanin）。此外，由于共同给药步骤也对癌细胞进行放射增敏，该方法另外包括辐射的施用以进一步降低癌细胞的克隆形成存活。该方法促进许多类型的癌细胞（包括白血病细胞，前列腺癌细胞，乳腺癌细胞，骨髓瘤细胞和淋巴瘤细胞）中的细胞凋亡和降低克隆生存。

2. 发明申请

WO2004060269A2 MDA-7 AND FREE RADICALS IN THE TREATMENT OF CANCER 审中-公开
标题翻译： MDA-7和免费治疗癌症的RADICAL
公开(公告)号：WO2004060269A2
公开(公告)日：2004-07-22
申请号：PCT/US2003/028512
申请日：2003-09-09
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK , VIRGINIA COMMONWEALTH UNIVERSITY , FISHER, Paul, B. , GOPALKRISHNAN, Rahul , LEBEDEVA, Irina , GRANT, Steven , YACOUB, Adly , DENT, Paul
发明人： FISHER, Paul, B. , GOPALKRISHNAN, Rahul , LEBEDEVA, Irina , GRANT, Steven , YACOUB, Adly , DENT, Paul
IPC分类号： A61K
CPC分类号： C12N15/86 , A61K38/1709 , A61K48/00 , C07K14/47 , C07K2319/23 , C12N2710/10343 , C12N2810/00
摘要： The present invention relates to methods of treating a cancer in a subject comprising generating within one or more cancer cells of a subject an effective amount of MDA-7 and an effective amount of one or more free radicals. The present invention further relates to methods of inhibiting proliferation or promoting death in a cancer cell of a subject comprising generating within one or more cancer cells of a subject an effective amount of MDA-7 and an effective amount of one or more free radicals. Generation of an effective amount of MDA-7 can occur by administering to the cancer cell an effective amount of an mda -7 nucleic acid, MDA-7 protein, functional equivalents of either of these molecules, by upregulation of the endogenous mda -7 gene, or by stabilization of the mda -7 mRNA. Generation of one or more free radicals in a cancer cell can occur by exposing the cancer cell to an effective amount of ionizing radiation, a free radical, a generator of a free radical, a ROS, a generator of a ROS, or a disruptor of mitochondrial membrane potential.
摘要翻译：本发明涉及治疗受试者的癌症的方法，包括在受试者的一个或多个癌细胞内产生有效量的MDA-7和有效量的一种或多种自由基。本发明还涉及在受试者的癌细胞中抑制增殖或促进死亡的方法，包括在受试者的一个或多个癌细胞内产生有效量的MDA-7和有效量的一种或多种自由基。有效量的MDA-7的产生可通过向癌细胞施用有效量的mda-7核酸，MDA-7蛋白，这些分子的功能等同物，通过上调内源性mda-7基因，或通过稳定mda-7mRNA。通过将癌细胞暴露于有效量的电离辐射，自由基，自由基的发生剂，ROS，ROS的产生剂或破坏剂的破坏剂，可以发生癌细胞中的一种或多种自由基的产生线粒体膜电位。

3. 发明申请

WO2004024160A1 COMBINATION OF A) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND B) A HISTONE DEACETYLASE INHIBITOR FOR THE TREATMENT OF LEUKEMIA 审中-公开
标题翻译： A）N- {5- [4-（4-甲基 - 哌嗪基 - 甲基） - 苯甲酰氨基] -2-甲基苯基} -4-（3-吡啶基）-2-嘧啶胺的组合和B）HISTONE脱乙酰基酶抑制剂用于治疗白血病
公开(公告)号：WO2004024160A1
公开(公告)日：2004-03-25
申请号：PCT/IB2003/004053
申请日：2003-09-10
申请人： VIRGINIA COMMONWEALTH UNIVERSITY , MCGUIRE VA MEDICAL CENTER 111K , DENT, Paul , GRANT, Steven , KRYSTAL, Geoffrey , YU, Chunrong
发明人： DENT, Paul , GRANT, Steven , KRYSTAL, Geoffrey , YU, Chunrong
IPC分类号： A61K31/506
CPC分类号： A61K31/404 , A61K31/165 , A61K31/166 , A61K31/19 , A61K31/405 , A61K31/4406 , A61K31/506 , A61K38/12 , A61K38/15 , A61K45/06 , A61K2300/00
摘要： The invention pertains to a combination of a histone deacetylase inhibitor and N-[5-[4-(4methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine or a pharmaceutically acceptable salt thereof for simultaneous, separate or sequential use for the treatment of leukemia and especially N-15-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl)-4-(3-pyridyl)-2-pyrimidine-resistant leukemia.
摘要翻译：本发明涉及组蛋白脱乙酰酶抑制剂和N- [5- [4-（4-甲基 - 哌嗪基 - 甲基） - 苯甲酰氨基] -2-甲基苯基} -4-（3-吡啶基）-2-嘧啶或药学上 -4-（3-吡啶基）-2-甲基苯基）-2-甲氧基苯甲酰胺嘧啶耐药性白血病。

4. 发明申请

WO2003084543A1 COMBINATION OF GLIVEC(STI571) WITH A CYCLIN-DEPENDENT KINASE INHIBITOR, ESPECIALLY FLAVOPIRIDOL IN THE TREATMENT OF CANCER 审中-公开
标题翻译： GLIVEC（STI571）与CYCLIN依赖性激酶抑制剂，特别是氟西汀在治疗癌症中的联合
公开(公告)号：WO2003084543A1
公开(公告)日：2003-10-16
申请号：PCT/IB2003/001418
申请日：2003-04-04
申请人： VIRGINIA COMMONWEALTH UNIVERSITY , THE GOVERNMENT OF THE UNITED STATES THE DEPARTMENT OF VETERANS AFFAIRS , DENT, Paul , GRANT, Steven , KRYSTAL, Geoffrey , YU, Chunrong
发明人： DENT, Paul , GRANT, Steven , KRYSTAL, Geoffrey , YU, Chunrong
IPC分类号： A61K31/506
CPC分类号： A61K31/445 , A61K31/506 , A61K2300/00
摘要： The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) a cyclin-dependent kinase inhibitor and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide and to its use for the treatment of cancer, especially of Bcr/Abl + leukemia resistant to compound of formula (I).
摘要翻译：本发明涉及同时，分开或顺序使用的组合，其包含（a）细胞周期蛋白依赖性激酶抑制剂和（b）4-（4-甲基哌嗪-1-基甲基）-N- [4-甲基-3- （4-吡啶-3-基）嘧啶-2-基氨基）苯基] - 苯甲酰胺及其用于治疗对式（I）化合物有抗性的癌症，特别是Bcr / Abl +白血病的用途。

5. 发明申请

WO2007035395A2 THERAPEUTIC COMPOSITIONS COMPRISING CHORIONIC GONADOTROPINS AND HMG COA REDUCTASE INHIBITORS 审中-公开
标题翻译：包含促性腺激素和HMG COA还原酶抑制剂的治疗组合物
公开(公告)号：WO2007035395A2
公开(公告)日：2007-03-29
申请号：PCT/US2006/035806
申请日：2006-09-14
申请人： VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATION , DENT, Paul
发明人： DENT, Paul
IPC分类号： A61K31/401
CPC分类号： A61K45/06 , A61K31/401 , A61K2300/00
摘要： The invention provides improved methods and compositions for the treatment of cancer in a subject comprising administering to said subject a therapeutically effective amount of a composition comprising a chorionic gonadotropin or a therapeutically active fragment or analogue thereof in combination with an HMG CoA reductase inhibitor. The compositions and methods may also comprise geranylgeranyltransferase inhibitors (GGTI) and farnesyltransferase inhibitors (FTI) instead of or in addition to the HMG CoA reductase inhibitors of the invention.
摘要翻译：本发明提供了用于治疗受试者中的癌症的改进的方法和组合物，其包括向所述受试者施用治疗有效量的包含绒毛膜促性腺激素或其治疗活性片段或类似物的组合物与 HMG CoA还原酶抑制剂。代替本发明的HMG CoA还原酶抑制剂或除此之外，组合物和方法还可以包含香叶基香叶基转移酶抑制剂（GGTI）和法尼基转移酶抑制剂（FTI）。

6. 发明申请

WO2021252099A2 ANTIMICROBIAL AND ANTITOXIN COMPOSITIONS AND METHODS FOR TREATMENT 审中-公开
公开(公告)号：WO2021252099A2
公开(公告)日：2021-12-16
申请号：PCT/US2021/030537
申请日：2021-05-04
申请人： VIRGINIA COMMONWEALTH UNIVERSITY
发明人： DENT, Paul
IPC分类号： A61K31/41 , A61K31/415 , C07D231/02 , C07D231/10 , C07D231/12 , A61K31/4985 , A61K31/506 , A61K31/519 , A61K31/53
摘要： Methods of treating coronavirus infections, ricin poisoning, and inhibiting growth of rod- shaped bacteria are provided. The methods include administering to a subject or contacting the bacteria with AR-12 or a derivative thereof or a multikinase inhibitor such as sorafenib tosylate or pazopanib, optionally in combination with one or more PDE5 inhibitors.

7. 发明申请

WO2016069854A1 ENHANCING THE ANTI-TUMOR, ANTI-VIRAL, AND ANTI-PROTOZOAN EFFECTS OF 2-AMINO-N-[4-[5-PHENANTHREN-2-YL-3-(TRIFLUOROMETHYL)PYRAZOL-1-YL] PHENYL]ACETAMIDE (OSU-03012) AND OTHER PHARMACEUTICAL DRUGS 审中-公开
标题翻译：增强2-氨基-N- [4- [5-苯并噻吩-2-基-3-（三氟甲基）吡唑-1-基]苯基]乙酰胺（OSU）的抗肿瘤，抗病毒和抗原佐剂效果 -03012）和其他药用药物
公开(公告)号：WO2016069854A1
公开(公告)日：2016-05-06
申请号：PCT/US2015/057974
申请日：2015-10-29
申请人： VIRGINIA COMMONWEALTH UNIVERSITY , ARNO THERAPEUTICS, INC.
发明人： DENT, Paul , ZUKIWSKI, Alexander , PRONIUK, Stefan
IPC分类号： A61K45/00 , A61K31/137 , A61K31/167 , A61K31/415 , A61K31/4188 , A61K31/4412 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/7036 , A61P25/28 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/20 , A61P31/22 , A61P35/00 , A61P43/00
CPC分类号： A61K31/137 , A61K31/167 , A61K31/415 , A61K31/44 , A61K31/4409 , A61K31/495 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K45/06 , Y02A50/393 , Y02A50/411 , Y02A50/473 , Y02A50/481 , A61K2300/00
摘要： Provided herein are compositions containing the drug OSU-03012 (AR-12) in combination with one or more drugs selected from multi-kinase inhibitors, HDAC inhibitors, folate antimetabolites, DNA alkylating agents, and sphingosine- 1 -phosphate receptor modulators. Also provided are phamiaceutical compositions containing two or more compounds selected from multi-kinase inhibitors, HDAC inhibitors, folate antimetabolites, DNA alkylating agents, and sphingosine- 1 -phosphate receptor modulators. These drug combinations are used as anti-cancer, anti-protozoal, and anti-viral agents.
摘要翻译：本文提供含有药物OSU-03012（AR-12）与一种或多种选自多激酶抑制剂，HDAC抑制剂，叶酸抗代谢物，DNA烷化剂和鞘氨醇-1-磷酸受体调节剂的组合物的组合物。还提供了含有两种或更多种选自多激酶抑制剂，HDAC抑制剂，叶酸抗代谢物，DNA烷化剂和鞘氨醇-1-磷酸受体调节剂的化合物的药物组合物。这些药物组合用作抗癌，抗原生动物和抗病毒剂。

8. 发明申请

WO2014093270A1 TROPISM MODIFIED CANCER TERMINATOR VIRUS (AD.5/3 CTV;AD.5/3-CTV-M7) 审中-公开
标题翻译： TROPISM改型癌症终末感染病毒（AD.5 / 3 CTV; AD.5 / 3-CTV-M7）
公开(公告)号：WO2014093270A1
公开(公告)日：2014-06-19
申请号：PCT/US2013/073989
申请日：2013-12-10
申请人： VIRGINIA COMMONWEALTH UNIVERSITY
发明人： FISHER, Paul, B. , SARKAR, Devanand , DENT, Paul
IPC分类号： A61K39/235 , A61K39/12 , A61K48/00 , A61P35/00
CPC分类号： A61K35/768 , A61K31/166 , A61K31/404 , A61K39/0011 , A61K45/06 , A61K2039/5254 , A61K2039/55511 , C12N7/00 , C12N15/86 , C12N2710/10032 , C12N2710/10321 , C12N2710/10332 , C12N2710/10343 , C12N2710/10371
摘要： A tropism modified cancer terminator virus (Ad.5/3-CTV; Ad.5/3-CTV-M7) has been found to have infectivity that is Coxsackie Adenoviral Receptor (CAR) independent. The Ad.5/3-CTV (Ad.5/3-CTV-M7) may be used alone or in combination with other therapeutic agents such as agents that augment reactive oxygen (ROS) production, HDAC inhibitors, MCL-1 inhibitors and Bcl-2 inhibitors to treat a variety of cancers particularly including malignant glioma (GBM), renal cancer, prostate cancer, and colorectal cancer.
摘要翻译：已经发现向性改良的癌症终止子病毒（Ad.5 / 3-CTV; Ad.5 / 3-CTV-M7）具有独立的柯萨奇腺病毒受体（CAR）感染性。 Ad5 / 3-CTV（Ad.5 / 3-CTV-M7）可以单独使用或与其他治疗剂组合使用，例如增加活性氧（ROS）产生的药物，HDAC抑制剂，MCL-1抑制剂和用于治疗各种癌症的Bcl-2抑制剂，特别包括恶性胶质瘤（GBM），肾癌，前列腺癌和结肠直肠癌。

9. 发明申请

WO2008074599A2 FAST, HIGH RESOLUTION DIGITAL-TO-ANALOG CONVERTER 审中-公开
标题翻译：快速，高分辨率数字到模拟转换器
公开(公告)号：WO2008074599A2
公开(公告)日：2008-06-26
申请号：PCT/EP2007/062877
申请日：2007-11-27
申请人： Telefonaktiebolaget LM Ericsson (publ) , DENT, Paul
发明人： DENT, Paul
IPC分类号： H03M1/82
CPC分类号： H03M1/667
摘要： A fast, high resolution digital-to-analog converter (DAC) is described herein. The DAC comprises a pulse generator, decay circuit, controller, and sample circuit. The pulse generator serially outputs pulses representing digits of a digital word least significant digit first. Each pulse generates a response in the decay circuit that decays over time according to a known decay response. One exemplary decay circuit comprises an RC circuit having an exponential decay response. The controller controls the timing of the pulses output by the pulse generator such that the period of each pulse relates to a predetermined decay amount. The sample circuit samples an output of the decay circuit at a sample time after the decay circuit receives the pulse for the most significant digit. The sampled output represents the analog value corresponding to the input digital word. The digital word may have any length, radix, or format.
摘要翻译：这里描述了一种快速，高分辨率的数模转换器（DAC）。 DAC包括脉冲发生器，衰减电路，控制器和采样电路。脉冲发生器首先串行地输出表示数字字最低有效数字的数字的脉冲。每个脉冲在衰减电路中产生响应，该响应根据已知的衰减响应随时间衰减。一个示例性的衰减电路包括具有指数衰减响应的RC电路。控制器控制由脉冲发生器输出的脉冲的定时，使得每个脉冲的周期与预定衰减量相关。采样电路在衰减电路接收到最高有效位的脉冲后的采样时间对衰减电路的输出进行采样。采样输出表示与输入数字字对应的模拟值。数字字可能有任何长度，基数或格式。

10. 发明申请

WO2004075459A2 TRANSMIT DIVERSITY AND SEPARATING MULTIPLE LOOPBACK SIGNALS 审中-公开
标题翻译：发射多样性和分离多重回波信号
公开(公告)号：WO2004075459A2
公开(公告)日：2004-09-02
申请号：PCT/US2004/003911
申请日：2004-02-10
申请人： ERICSSON INC. , DENT, Paul , ZANGI, Kambiz
发明人： DENT, Paul , ZANGI, Kambiz
IPC分类号： H04L
CPC分类号： H04L25/03343 , H04B1/7105 , H04B7/005 , H04B7/022 , H04B7/0615 , H04B7/0617 , H04B7/0619 , H04L1/243 , H04L25/0202 , H04L25/0204 , H04L25/0212 , H04L25/0226 , H04L25/0228 , H04L25/0244 , H04L27/367 , H04W52/42
摘要： A wireless communication network processes composite loop-back signals received at one or more network antennas from a plurality of mobile stations, each transmitting an individual, mobile-specific loop-back signal. Using its knowledge of the prior network-transmitted signal(s) from which the mobile stations derive their individual loop-back signals, and its knowledge of the mobile-specific loop-back signal modifications made by each of the mobile stations, the network derives mobile-specific downlink channel information based on processing the composite loop-back signals. That is, use of the mobile-specific loop-back signals enables the network to determine downlink channel estimates as between each participating network antenna and each participating mobile station to be used for transmit signal interference and/or power precompensation, for example. Mobile stations incorporate loop-back signal sample processors used to impart mobile-specific modifications to signal samples obtained from network-transmitted signals. The modified signal samples, thus "imprinted," are then transmitted back to the network.
摘要翻译：无线通信网络处理在多个移动站的一个或多个网络天线处接收的复合环回信号，每个移动台发送单独的移动专用环回信号。使用其关于移动台从其中导出其各自的环回信号的先前的网络发送信号的知识以及由每个移动站进行的移动专用环回信号修改的知识，网络导出基于处理复合环回信号的移动专用下行链路信道信息。也就是说，使用移动专用环回信号使得网络能够确定例如在每个参与的网络天线和每个参与的移动台之间的下行链路信道估计，以用于发射信号干扰和/或功率预补偿。移动台包含环回信号采样处理器，用于对从网络传输信号获得的信号样本进行移动专用修改。然后将经修改的信号样本“印迹”传送回网络。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式